"FDA-approved" may be the most trusted phrase in American health care. It is also one of the most misunderstood. In depression treatment, where approved, cleared, off-label, and compounded products now sit side by side, those misunderstandings can steer people toward the wrong choice or away from a good one.
The phrase clearly carries weight. Across ten Midwest states, our summer questionnaire reached 443 adults and turned up 19 percent for whom FDA approval alone would settle whether to try an unfamiliar depression treatment, plus 40 percent who rated it a big factor; a mere 14 percent shrugged it off. With that much riding on two words, it helps to know their limits. All poll numbers below are final.
Misreading 1: "Approved means it will work on me."
Approval means the manufacturer showed, usually through clinical trials, that benefits beat risks in the particular patients studied, with one particular condition. It does not predict how any one person will respond. Depression treatments that are approved and effective across a population still help one person greatly, another slightly, and a third not at all.
Approval starts a conversation with a clinician; your history decides the rest.
Misreading 2: "If a drug is approved, it is approved for everything it is used for."
Approval is tied to a specific use. Approval for one condition does not extend itself to others. Ketamine is a good example. The FDA approved generic ketamine as an anesthetic. Infusing it for depression, as many clinics do, is off-label. Spravato, the esketamine brand, is a cousin but a separate product, and its approval is for depression that has resisted other treatment.
So "ketamine is FDA-approved" is technically true and practically misleading when the subject is depression. The question to ask is always: approved for what?
Misreading 3: "Off-label means illegal or dangerous."
Neither is automatically true. Once a drug is approved, licensed prescribers can legally use it for other purposes. Off-label prescribing is common throughout medicine, and sometimes the supporting evidence is strong.
What off-label does mean is that the specific use has not been through FDA review. The evidence may come from smaller studies or clinical experience. That is a reason to ask questions, not a reason to panic. A good prescriber will explain why they recommend an off-label option and whether an approved alternative exists.
Misreading 4: "FDA-cleared is a lesser, unreviewed version of approved."
Clearance is a different pathway, used for many medical devices, not a watered-down one. TMS treats depression with a magnetic coil on the scalp and no medication, and its clearance covers adults whose major depression persisted through antidepressants. The clinic that says "cleared" rather than "approved" is using the correct term, not dodging.
That matters for the many people who want a drug-free option. Our respondents split oddly here: 64 percent cared about avoiding drugs, while TMS rang a bell for only 25 percent.
Misreading 5: "An FDA-approved clinic" is a meaningful phrase.
The FDA reviews drugs and devices. It does not approve clinics. When you see "FDA-approved clinic" or "FDA-registered facility," look for the specific product and condition behind it.
There is a related point that often confuses people. Spravato may only be dispensed at sites certified under its safety program, which watch each patient for two hours or more after every dose. That certification is real, but it belongs to one product and is no blanket FDA seal on the clinic. Brain Recovery Centers explains how the Spravato certification and visits work.
Misreading 6: "If it's approved, insurance has to cover it."
Approval makes coverage more likely but does not make it certain. Most insurers require prior authorization for newer depression treatments, often asking for proof that standard medications did not work. Coverage terms vary widely between plans.
And coverage is what most people put first. With two choices for what counts most in a provider, 85 percent of respondents named coverage, and FDA approval, at 27 percent, ran just ahead of fast results. A different question found 65 percent calling coverage deciding or big for whether they would try anything.
A bonus misreading: "Compounded means generic."
A generic drug is FDA-approved as equivalent to a brand-name drug. A compounded drug is made up by a pharmacist for one patient and has no FDA approval. Some at-home ketamine products are compounded. That alone does not make them unsafe, yet no FDA review ever vetted them for safety or effectiveness.
Why these misreadings persist
Part of the problem is awareness. Spravato is the lone ketamine-based product approved for treatment-resistant depression, and 73 percent of respondents in our poll had never heard of it. Unfamiliar treatments blur easily into one fuzzy idea called "ketamine."
Another part is how people search. The 319 respondents who wrote out their likely search terms used phrases like "depression medicine alternatives" and "help with depression," not product names or regulatory terms. Search results for those phrases can mix approved and unapproved options without making the difference clear.
What to do instead
- Ask "approved for what?" every time you see the phrase.
- Ask whether your intended use is on-label or off-label.
- For devices, ask what the device is cleared to treat.
- For medications prepared by a pharmacy, ask whether they are compounded.
- Check coverage separately. Approval does not settle it.
Most people would take these questions to their doctor, and that is the right place. A doctor vouching for it would be enough for 74 percent of our respondents to give a new treatment a try. Fit is a clinical call, and the label is just one input to it.
If thoughts of suicide have crept in, reach out today rather than someday. At 988, by phone or by text, the Suicide and Crisis Lifeline is staffed through the night.
Methodology
Pollfish put study 395586438 before members of its consumer panel; the last responses came in on June 23, 2026. We report 443 completes from adults 18 to 64 residing in Indiana, Minnesota, Oklahoma, Nebraska, Illinois, Wisconsin, Missouri, Ohio, Iowa and Kansas; all consented at a screener. For multi-select questions, each number reflects the share of all 443. These data are final, post-validation. It was the publisher who ordered and financed the work.